KemPharm (NASDAQ:KMPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The firm presently has a $1.25 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 27.55% from the stock’s previous close.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

KMPH has been the subject of a number of other reports. ValuEngine upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Oppenheimer reduced their target price on shares of KemPharm from $8.00 to $3.00 and set an “outperform” rating for the company in a report on Thursday, May 23rd. Finally, HC Wainwright began coverage on shares of KemPharm in a report on Wednesday, June 19th. They set a “buy” rating and a $3.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $2.42.

Shares of NASDAQ:KMPH opened at $0.98 on Friday. The stock has a market capitalization of $30.06 million, a price-to-earnings ratio of -0.39 and a beta of 1.39. KemPharm has a 1-year low of $0.96 and a 1-year high of $5.47. The company has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.72.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.09. As a group, research analysts predict that KemPharm will post -1.34 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in KemPharm by 134.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock valued at $2,341,000 after acquiring an additional 767,100 shares during the last quarter. BlackRock Inc. raised its holdings in KemPharm by 21.7% in the 2nd quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock valued at $186,000 after acquiring an additional 19,001 shares during the last quarter. Iowa State Bank raised its holdings in KemPharm by 90.6% in the 2nd quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock valued at $77,000 after acquiring an additional 21,000 shares during the last quarter. RDA Financial Network acquired a new position in KemPharm in the 2nd quarter valued at $28,000. Finally, Wedbush Securities Inc. acquired a new position in KemPharm in the 1st quarter valued at $72,000. Hedge funds and other institutional investors own 30.65% of the company’s stock.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Recommended Story: What are popular green investing opportunities?

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.